1. Home
  2. ECBK vs VERU Comparison

ECBK vs VERU Comparison

Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$17.08

Market Cap

153.1M

Sector

Finance

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.39

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECBK
VERU
Founded
1919
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.1M
41.7M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
ECBK
VERU
Price
$17.08
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
6.0K
52.2K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.55
$0.36
52 Week High
$20.05
$4.59

Technical Indicators

Market Signals
Indicator
ECBK
VERU
Relative Strength Index (RSI) 43.47 42.29
Support Level $15.16 $2.15
Resistance Level $17.38 $2.70
Average True Range (ATR) 0.31 0.13
MACD -0.07 -0.02
Stochastic Oscillator 29.14 0.00

Price Performance

Historical Comparison
ECBK
VERU

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: